Urgent Access to Effective Treatments to End the Agony of Cluster Headaches

Cluster headache is one of the most excruciatingly painful conditions known to medicine, compared by those suffering to having a red-hot ice pick driven into the eye. It is also called "suicide headache" because some patients choose to end their lives to escape the pain. There is no known cure, and standard existing medical options are unable to consistently and reliably prevent or abort attacks. An estimated 17,000 Canadian adults endure this unbearable pain every year.

Countless patients have reported previously unattainable relief using certain compounds of the indoleamine chemical family, which interact with serotonin receptors.^[1] Psilocybin, LSD, 5-MeO-DALT and BOL-148 (a non-hallucinogenic derivative of LSD) have been found to be effective in preventing attacks, and N,N-DMT has been found^[2] to abort attacks within seconds and also have some preventative effects, even at sub-hallucinogenic doses. These are not isolated anecdotes: hundreds of patients have reported these effects in published scientific surveys, some clinical trials support these claims, and limited use in clinical settings has also demonstrated the effectiveness. In patient support groups and in conferences organised by a major patient advocacy group, patients relate the successes they have had in ending their pain through the use of these substances.

Based on an analysis of all the evidence, we have no doubt at all that these substances have medical value in preventing the excruciating pain of cluster headache where other therapies have failed. Although caution must always be exercised, these compounds are generally regarded as safe substances with low toxicity.^[3]

None of these substances has yet been approved for the medical treatment of cluster headache. Conducting large-scale clinical trials is complicated by the difficulty to recruit patients with this relatively rare condition, and the lack of funding to study these non-proprietary compounds.

In Canada, there are limited but evolving pathways for access to these compounds for cluster headache treatment. While these substances remain classified as controlled substances under the Controlled Drugs and Substances Act, Health Canada has recently begun granting access through two key mechanisms: the Special Access Program (SAP) and Section 56 exemptions. In June 2024, Health Canada approved the first SAP request for a cluster headache patient to receive psilocybin therapy, and subsequently granted a Section 56 exemption allowing them to possess psilocybin for self-administration.^[4] These groundbreaking decisions followed a federal court ruling that found the previous denial of access "unreasonable." Despite this progress, these approvals remain case-by-case exceptions rather than a systematic approach.

This situation demands the same urgency as providing anaesthesia for major surgical procedures.

We call on the Canadian government to institute the following measures:^[5]